Educational Programs on Biosimilar Insulin Benefit Both Patients and Providers

Center for Biosimilars (07/18/18) Davio, Kelly

For diabetes patients who take biosimilar or follow-on insulins, education for both the provider and patient can enhance care, according to new research. A U.S. study, presented at the American Diabetes Association's 78th Scientific Sessions in Orlando, focused on whether an online continuing medical education (CME) roundtable activity could increase clinical knowledge and competence among providers in diabetes and endocrinology. At baseline, primary care providers (PCPs) were significantly less knowledgeable about follow-on basal insulin use compared with specialists. However, after completing the video-based program, both groups showed substantially greater knowledge about follow-on insulin use. Furthermore, over 60 percent of PCPs and 37 percent of specialists said they felt more confident when switching patients to follow-on insulin glargine after taking the activity. The findings highlight the benefits of this type of CME program for increasing providers' clinical knowledge and competence about follow-on insulin, the researchers report. Also at the meeting, researchers from India reported on a structured patient education program for more than 10,000 people with type 2 diabetes who used biosimilar insulin therapy with human or basal insulin. The Insulin Therapy Assistance Program — which instructed patients about diabetes, lifestyle management, and other factors — led to meaningful improvements in the participants' glycemic parameters when measured at three, six and nine months after starting the program, according to the researchers.

Read More

Recent Stories
The RightSTEPS Initiative: Continuing Education Impact on Clinicians' Optimal Medical Therapy Practices for Chronic Heart Failure

New Grant Program to Build Trust and Support Innovations in Diversity, Equity and Inclusion

The Rise and Impact of Microlearning in CME During COVID-19